C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders.
about
Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer modelp25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophyAnosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology.CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's diseasePrevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body DisordersNeuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinDecreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.Tau-positive glial cytoplasmic granules in multiple system atrophy.Inflammation in the early stages of neurodegenerative pathologySubventricular zone under the neuroinflammatory stress and Parkinson's disease.The Lewy body in Parkinson's disease and related neurodegenerative disorders.Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases.Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level.alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity.Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.The role of NAC in amyloidogenesis in Alzheimer's disease.Comparative study of commercially available anti-alpha-synuclein antibodies.
P2860
Q24305472-8EE60AF7-4DE1-4E16-AD75-891BC8E793FFQ24682056-1B00CB3E-13C2-4A7C-B3B5-2E8E07BD45F0Q30495523-8B02AD32-B5FF-49FF-A33B-6574240407CFQ33760744-D36DB229-1257-4568-BE03-D3131868C341Q33874572-65D91CB5-C573-43AF-902D-941712761C8DQ34648491-54B49FB2-9A5F-412D-98A9-623347408F48Q36658992-2C74FA32-8A1F-48C1-B7F6-FF98E3ECF4EBQ36746491-5FCE114E-7C24-4207-97C9-093CD33D45D2Q37808274-B537854B-9E3F-4BB1-AC50-B224AACE22C1Q37912590-478A1963-86A8-4837-82CC-F32E03E0326DQ37970601-121BFAEA-546E-4B5A-BF0D-6AFD758D11ECQ38012653-9336E7C4-F44D-4EC4-B024-3B3B086B103AQ38037524-8F32E865-166B-4CBA-8481-5E7ED62A7FDAQ39309731-990A11FA-C222-41BC-B80F-8FC9D7F08452Q40190309-6A1CFA71-B77B-47ED-BA26-584A0DA86BC8Q42711308-402F9FE5-168E-4F15-A680-741F74494127Q42857209-B4CF2B8C-35DE-4C47-8518-0E7058C69995Q48566458-4C10A6E9-9022-4006-8D0A-84CA951CEA80
P2860
C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@ast
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@en
type
label
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@ast
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@en
prefLabel
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@ast
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@en
P2093
P356
P1476
C-terminal alpha-synuclein imm ...... n neurodegenerative disorders.
@en
P2093
P2888
P304
P356
10.1007/PL00007441
P577
2000-03-01T00:00:00Z
P6179
1019362575